vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $194.8M, roughly 1.9× TOMPKINS FINANCIAL CORP). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 8.6%, a 40.8% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 12.1%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $31.9M). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
LIVN vs TMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $194.8M |
| Net Profit | $30.9M | $96.2M |
| Gross Margin | 65.2% | — |
| Operating Margin | 11.8% | 71.7% |
| Net Margin | 8.6% | 49.4% |
| Revenue YoY | 12.1% | 152.7% |
| Net Profit YoY | -44.7% | 388.9% |
| EPS (diluted) | $0.57 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $194.8M | ||
| Q3 25 | $357.8M | $87.4M | ||
| Q2 25 | $352.5M | $82.6M | ||
| Q1 25 | $316.9M | $81.7M | ||
| Q4 24 | $321.8M | $77.1M | ||
| Q3 24 | $318.1M | $76.6M | ||
| Q2 24 | $318.6M | $72.7M | ||
| Q1 24 | $294.9M | $72.8M |
| Q4 25 | $30.9M | $96.2M | ||
| Q3 25 | $26.8M | $23.7M | ||
| Q2 25 | $27.2M | $21.5M | ||
| Q1 25 | $-327.3M | $19.7M | ||
| Q4 24 | $55.9M | $19.7M | ||
| Q3 24 | $33.0M | $18.6M | ||
| Q2 24 | $16.3M | $15.7M | ||
| Q1 24 | $-41.9M | $16.9M |
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — | ||
| Q1 24 | 70.3% | — |
| Q4 25 | 11.8% | 71.7% | ||
| Q3 25 | 15.1% | 35.6% | ||
| Q2 25 | 15.4% | 34.2% | ||
| Q1 25 | 15.3% | 31.6% | ||
| Q4 24 | 11.5% | 33.4% | ||
| Q3 24 | 11.2% | 32.0% | ||
| Q2 24 | 12.6% | 28.3% | ||
| Q1 24 | 5.5% | 30.4% |
| Q4 25 | 8.6% | 49.4% | ||
| Q3 25 | 7.5% | 27.1% | ||
| Q2 25 | 7.7% | 26.0% | ||
| Q1 25 | -103.3% | 24.1% | ||
| Q4 24 | 17.4% | 25.5% | ||
| Q3 24 | 10.4% | 24.3% | ||
| Q2 24 | 5.1% | 21.6% | ||
| Q1 24 | -14.2% | 23.2% |
| Q4 25 | $0.57 | $6.72 | ||
| Q3 25 | $0.49 | $1.65 | ||
| Q2 25 | $0.50 | $1.50 | ||
| Q1 25 | $-6.01 | $1.37 | ||
| Q4 24 | $1.04 | $1.39 | ||
| Q3 24 | $0.60 | $1.30 | ||
| Q2 24 | $0.30 | $1.10 | ||
| Q1 24 | $-0.78 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $132.8M |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $938.4M |
| Total Assets | $2.6B | $8.7B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $132.8M | ||
| Q3 25 | $646.1M | $193.5M | ||
| Q2 25 | $593.6M | $212.6M | ||
| Q1 25 | $738.4M | $193.1M | ||
| Q4 24 | $428.9M | $134.4M | ||
| Q3 24 | $346.4M | $132.3M | ||
| Q2 24 | $329.2M | $70.9M | ||
| Q1 24 | $309.2M | $57.1M |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $938.4M | ||
| Q3 25 | $1.2B | $788.8M | ||
| Q2 25 | $1.1B | $761.8M | ||
| Q1 25 | $1.0B | $741.4M | ||
| Q4 24 | $1.3B | $713.4M | ||
| Q3 24 | $1.3B | $719.9M | ||
| Q2 24 | $1.2B | $674.6M | ||
| Q1 24 | $1.2B | $667.9M |
| Q4 25 | $2.6B | $8.7B | ||
| Q3 25 | $2.6B | $8.5B | ||
| Q2 25 | $2.5B | $8.4B | ||
| Q1 25 | $2.6B | $8.2B | ||
| Q4 24 | $2.5B | $8.1B | ||
| Q3 24 | $2.5B | $8.0B | ||
| Q2 24 | $2.5B | $7.9B | ||
| Q1 24 | $2.5B | $7.8B |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $38.9M |
| Free Cash FlowOCF − Capex | $50.2M | $31.9M |
| FCF MarginFCF / Revenue | 13.9% | 16.4% |
| Capex IntensityCapex / Revenue | 8.9% | 3.6% |
| Cash ConversionOCF / Net Profit | 2.67× | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $38.9M | ||
| Q3 25 | $85.1M | $34.9M | ||
| Q2 25 | $62.9M | $18.9M | ||
| Q1 25 | $24.0M | $22.2M | ||
| Q4 24 | $78.7M | $95.0M | ||
| Q3 24 | $51.0M | $21.2M | ||
| Q2 24 | $43.4M | $27.3M | ||
| Q1 24 | $10.0M | $23.2M |
| Q4 25 | $50.2M | $31.9M | ||
| Q3 25 | $62.2M | $33.9M | ||
| Q2 25 | $47.8M | $18.3M | ||
| Q1 25 | $13.2M | $20.9M | ||
| Q4 24 | $68.3M | $88.8M | ||
| Q3 24 | $32.8M | $18.9M | ||
| Q2 24 | $31.2M | $26.3M | ||
| Q1 24 | $3.6M | $21.9M |
| Q4 25 | 13.9% | 16.4% | ||
| Q3 25 | 17.4% | 38.8% | ||
| Q2 25 | 13.6% | 22.1% | ||
| Q1 25 | 4.2% | 25.5% | ||
| Q4 24 | 21.2% | 115.1% | ||
| Q3 24 | 10.3% | 24.7% | ||
| Q2 24 | 9.8% | 36.2% | ||
| Q1 24 | 1.2% | 30.0% |
| Q4 25 | 8.9% | 3.6% | ||
| Q3 25 | 6.4% | 1.1% | ||
| Q2 25 | 4.3% | 0.8% | ||
| Q1 25 | 3.4% | 1.7% | ||
| Q4 24 | 3.2% | 8.1% | ||
| Q3 24 | 5.7% | 2.9% | ||
| Q2 24 | 3.8% | 1.3% | ||
| Q1 24 | 2.2% | 1.9% |
| Q4 25 | 2.67× | 0.40× | ||
| Q3 25 | 3.18× | 1.47× | ||
| Q2 25 | 2.32× | 0.88× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | 1.41× | 4.82× | ||
| Q3 24 | 1.55× | 1.14× | ||
| Q2 24 | 2.65× | 1.74× | ||
| Q1 24 | — | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
TMP
Segment breakdown not available.
